Amphastar Pharmaceuticals Inc

AMPH is in a Stage 1 early consolidation after a terminal decline, trading in a tight range around its short EMAs and 50 DMA. Mean-reversion eligibility and strong free-cash-flow metrics support a tactical bounce from the well-defended demand zone, consistent with the Free Cash Flow + Buybacks strategy’s emphasis on high-quality entry points. However, indicators and volume remain neutral with no clear timing edge. Execution should be patient for pullback-based entries near support.

• ↑High earnings yield (2.2%) and book-to-price ratio (1.92) signal deep value.
• ↑FDA approved ipratropium bromide HFA generic inhaler, first mover in segment.
• ↓Gross margin contracted from 50% in Q1’25; glucagon revenues down 27% YoY.